Position in CVM
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$595,358
+$480,152 QoQ
Shares Held
572,460
+1495.0% QoQ
Ownership
3.25%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1
of 41 holders
Holding Since
Mar 2022
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CVM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RENAISSANCE TECHNOLOGIES LLC holds $3,951,130,026 across 312 Biotechnology names. CVM ranks #206 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
13,427,993 | $730,617,099 | |
| 2 | CORT |
Corcept Therapeutics Inc
|
5,261,628 | $457,498,554 | |
| 3 | INCY |
Incyte Corp
|
3,512,132 | $398,135,283 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
320,008 | $158,957,573 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
562,073 | $135,442,730 | |
| 6 | RPRX |
Royalty Pharma plc
|
1,935,800 | $108,540,306 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
1,833,079 | $104,137,217 | |
| 8 | GMAB |
Genmab A/S
|
3,517,850 | $96,635,339 |
All Filings in CVM
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $595,358 | 572,460 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $115,206 | 35,890 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $81,035 | 15,406 | Shares | Sole | 2026-02-12 | |
| 2024-06-30 | $201,607 | 173,800 | Shares | Sole | 2024-08-09 | |
| 2024-03-31 | $255,557 | 133,800 | Shares | Sole | 2024-05-13 | |
| 2023-12-31 | $107,983 | 39,700 | Shares | Sole | 2024-02-13 | |
| 2022-12-31 | $56,458 | 24,025 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $40,735 | 13,183 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $984,973 | 218,883 | Shares | Sole | 2022-08-12 | |
| 2022-03-31 | $3,037,430 | 772,883 | Shares | Sole | 2022-05-13 | |
| No filing history on record for this holder in this stock. | ||||||